Cidara Therapeutics, Inc. (CDTX) Price Target Raised to $16.00
Cidara Therapeutics, Inc. (NASDAQ:CDTX) had its target price boosted by HC Wainwright from $14.00 to $16.00 in a report issued on Thursday. They currently have a buy rating on the biotechnology company’s stock.
Several other research firms have also issued reports on CDTX. Zacks Investment Research upgraded shares of Cidara Therapeutics from a hold rating to a buy rating and set a $8.75 price target on the stock in a research report on Wednesday, October 25th. Cantor Fitzgerald reaffirmed a buy rating and issued a $15.00 price objective on shares of Cidara Therapeutics in a research note on Tuesday, September 26th. ValuEngine raised shares of Cidara Therapeutics from a strong sell rating to a sell rating in a research note on Friday, July 14th. Finally, WBB Securities raised shares of Cidara Therapeutics from a sell rating to a hold rating in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $13.39.
Cidara Therapeutics (CDTX) traded up $0.15 during trading on Thursday, reaching $7.80. 54,800 shares of the company’s stock traded hands, compared to its average volume of 84,215. The company has a current ratio of 7.69, a quick ratio of 7.49 and a debt-to-equity ratio of 0.16. Cidara Therapeutics has a 12-month low of $5.60 and a 12-month high of $11.85.
Cidara Therapeutics (NASDAQ:CDTX) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.21. sell-side analysts predict that Cidara Therapeutics will post -3.42 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Cidara Therapeutics, Inc. (CDTX) Price Target Raised to $16.00” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/cidara-therapeutics-inc-cdtx-price-target-raised-to-16-00/1698485.html.
In related news, CEO Jeffrey Stein bought 7,350 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was bought at an average price of $6.79 per share, with a total value of $49,906.50. Following the purchase, the chief executive officer now directly owns 51,851 shares of the company’s stock, valued at approximately $352,068.29. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 18.90% of the company’s stock.
Several large investors have recently modified their holdings of the business. BB Biotech AG boosted its stake in shares of Cidara Therapeutics by 5.6% during the 2nd quarter. BB Biotech AG now owns 1,102,578 shares of the biotechnology company’s stock valued at $8,269,000 after buying an additional 58,754 shares during the period. Broadfin Capital LLC boosted its stake in shares of Cidara Therapeutics by 45.0% during the 2nd quarter. Broadfin Capital LLC now owns 816,275 shares of the biotechnology company’s stock valued at $6,122,000 after buying an additional 253,400 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Cidara Therapeutics during the 2nd quarter valued at $650,000. Susquehanna International Group LLP acquired a new stake in shares of Cidara Therapeutics during the 2nd quarter valued at $350,000. Finally, Trellus Management Company LLC acquired a new stake in shares of Cidara Therapeutics during the 2nd quarter valued at $338,000. 66.11% of the stock is owned by institutional investors.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.